Advanced Solid Tumor
Conditions
Keywords
Antibody Drug Conjugate, Phase 1/2, Solid Tumors
Brief summary
This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.
Detailed description
This is an open-label, dose-escalation, and expansion study to determine the Maximum Tolerated Dose (MTD) and select the recommended Phase 2 dose (RP2D). Dose escalation follows a conventional 3+3 design; successive cohorts of 3 to 6 participants each will be evaluated in sequential escalating doses of single-agent IMGC936. Upon completion of the dose-escalation phase of the study, following determination of the RP2D, up to 5 expansion cohorts may be opened in tumor types selected from those enrolled in dose escalation. Participants with relapsed or refractory, unresectable locally advanced or metastatic solid tumors including non-squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), gastroesophageal cancer, or pancreatic cancer will be enrolled. IMGC936 is administered via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter, at the assigned dose for each cohort during dose escalation, and at the RP2D for expansion. Infusion duration will vary depending on dose and participant tolerability. Sentinel dosing will be used for the first 2 dose levels of dose escalation. The first administration of IMGC936 in participants at the first 2 dose levels of dose escalation will be staggered by at least 48 hours. The dose-limiting toxicity (DLT) evaluation period is 21 days. Participants may continue on study drug until disease progression, adverse event (AE) requiring discontinuation, DLT during evaluation window, pregnancy, death, investigator decision, lost to follow up (LTFU), major protocol deviation requiring discontinuation, withdrawal of consent, or sponsor, investigator or regulatory agency terminates the study. Tumor assessments are performed every 6 weeks (Q6W) while on study drug then every 12 weeks (Q12W). Tumor assessments continue until discontinuation criteria are met. If feasible, participants who discontinue study drug for reasons other than progressive disease (PD) (e.g., toxicity) should continue to undergo tumor assessments Q12W as post-treatment follow up until evidence of PD, initiation of another anticancer therapy, withdrawal of consent, LTFU, death, or end of study. Post-treatment follow up also includes following ongoing treatment emergent adverse events (TEAEs) until the event has resolved to baseline grade, the event is assessed by the investigator as stable, initiations of another anticancer therapy, withdrawal of consent, LTFU, death, or it has been determined that study drug or participation is not the cause of the AE.
Interventions
DRUGIMGC936
Antibody Drug Conjugate
Sponsors
MacroGenics
ImmunoGen, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants with histologically proven, relapsed or refractory, unresectable locally advanced or metastatic non-squamous NSCLC, TNBC, CRC, gastroesophageal cancer, or pancreatic cancer for whom no therapy with demonstrated clinical benefit is available. 1. NSCLC: Participants must have been treated with 1 to 4 prior lines of systemic therapy with no more than 2 chemotherapy containing lines. 2. TNBC: Participants must have been treated with 1 to 4 prior lines of systemic therapy for metastatic disease, excluding adjuvant therapies. 3. CRC: Participants must have been treated with 1 to 3 prior lines of systemic therapy. 4. Gastroesophageal cancer: Participants must have been treated with 1 to 3 prior lines of systemic therapy. 5. Pancreatic cancer: Participants must have been treated with 1 to 3 prior lines of systemic therapy, with no more than 2 chemotherapy containing lines. 2. Either measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and documented by computed tomography (CT) and/or magnetic resonance imaging (MRI) obtained within 28 days of Cycle 1 Day 1 (C1D1). * Dose escalation: Participants may have non-measurable or measurable disease * Dose expansion: Participants must have measurable disease 3. Age ≥ 18 years old. 4. Archival formalin-fixed paraffin-embedded (FFPE) tissue must be available. Participants may undergo a fresh tumor biopsy using a low risk, medically routine procedure to obtain a specimen for testing if a tumor sample is not available. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. If ECOG performance status is an inappropriate performance measurement for participant enrollment (for example, chronically non-ambulatory), then Karnofsky performance status must be ≥ 70. 6. Life expectancy ≥ 12 weeks. 7. Acceptable laboratory parameters as follows: * Platelet count ≥ 75 × 1000/microliter (μL) without transfusion within 28 days prior to initiation of study drug. * Absolute neutrophil count ≥ 1.5 × 1000/μL in the absence of any growth factor support within 21days prior to initiation of study drug. * Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN); for participants with hepatic metastases, ALT and AST ≤ 5 × ULN. * Total bilirubin ≤ 1.5 × ULN, except participants with Gilbert's syndrome, who may enroll if the conjugated bilirubin is within normal limits. * Estimated glomerular filtration rate (eGFR) \>30 milliliters (mL)/ minute (min)/1.73 square meter (m\^2) or an estimated creatinine clearance of \>30 mL/min. * Urinalysis protein and white occult blood cells within normal limits. * Negative serum pregnancy test for females of childbearing potential (FOCBP). 8. FOCBP, defined as not surgically sterilized (hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) and between menarche and 1-year post menopause, must have a negative serum pregnancy test performed within 72 hours prior to initiation of study drug administration. Female participants must abstain from egg donation during the study. 9. FOCBP and male participants with partners of FOCBP must agree to use highly effective methods of contraception, from the time of consent through 28 weeks after discontinuation of study drug administration. Male participants must abstain from sperm donation during the study. 10. FOCBP is not pregnant or breastfeeding, or a male participant is not expecting to father children within the projected duration of the study, starting with screening visit through 28 weeks after the last dose of study drug.
Exclusion criteria
1. Active central nervous system (CNS) disease within the last 6 months. 2. Active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision. 3. Participants who had prior therapies within the specified times below: * Systemic antineoplastic therapy at least 5 half-lives or 4 weeks (whichever is shorter) prior to initiation of study drug. * Mediastinal or pelvic radiation therapy within 6 weeks prior to initiation of study drug administration. Palliative, limited field radiation for symptom control to soft tissues, or bone lesions within 2 weeks prior to initiation of study drug. 4. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities (except alopecia). 5. Clinically significant cardiovascular disease including but not limited to: * Myocardial infarction or unstable angina within 6 months prior to initiation of study drug. * Stroke or transient ischemic attack within 6 months prior to initiation of study drug. * Current clinically significant cardiac arrhythmias, for example, atrial fibrillation that are not well controlled with optimal medical intervention. * Current uncontrolled hypertension: systolic blood pressure \> 160 millimeters of mercury (mmHg), diastolic blood pressure \> 100 mmHg. * Current congestive heart failure (New York Heart Association class III-IV). * Current pericarditis or clinically significant pericardial effusion. * Current myocarditis. * Left ventricular ejection fraction (LVEF) of \< 50% by scan * QTc interval \> 480 milliseconds (msec) 6. Clinically significant pulmonary compromise, including pneumonia, pneumonitis, or a requirement for supplemental oxygen (excluding for sleep apnea) or history of ≥ Grade 3 drug-induced or radiation pneumonitis. 7. Serious concurrent illness or clinically relevant active infection, including, but not limited to the following: * Active hepatitis B or C infection (whether or not on active antiviral therapy). * Human immunodeficiency virus infection. * Cytomegalovirus infection. * Active COVID-19/SARS-CoV-2 infection. While SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines/standards. * Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to initiation of study drug. 8. History of prior bone marrow, stem cell, or solid organ transplantation. 9. Second primary invasive malignancy that has not been in remission for greater than 2 years except nonmelanoma skin cancer; cervical carcinoma in situ on biopsy; or squamous intraepithelial lesion on Pap smear; localized prostate cancer (Gleason score \< 6); or resected melanoma in situ. 10. Major trauma or major surgery within 4 weeks prior to initiation of study drug. 11. Any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the study site. 12. Known hypersensitivity to any ingredient or any excipient contained in the drug formulation 13. Vaccination with any live virus vaccine within 4 weeks prior to initiation of study drug. Inactivated annual influenza vaccination is allowed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Up to approximately 3 years | An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AEs with onset date between the first dose of IMGC936 and date of the last dose of IMGC936 + 30 days (inclusive) or date of the first anti-cancer therapy, whichever was earlier. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. |
| Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | Cycle 1 (21 days for Schedule A and 28 days for Schedule B) | DLTs were defined based on TEAEs or abnormal laboratory values that met DLT criteria. Hematologic DLT: Grade 4 neutropenia lasting \>7 days; ≥Grade 3 febrile neutropenia Grade 4 thrombocytopenia; Grade 3 thrombocytopenia associated with bleeding; ≥Grade 3 hemolysis. Non-hematologic DLT: Any ≥Grade 3 non-hematologic event, including Grade 3 ocular symptoms and signs; Grade 2 AEs that were prolonged inordinately; • Hepatic laboratory abnormalities meeting Hy's law criteria; Eye pain or reduction in visual acuity that did not respond to topical ophthalmic therapy. Hepatic DLT: Any elevation of ≥1 transaminases \>8 \* upper limit of normal (ULN); Any Grade 3 elevation of ≥1 transaminases \>5.0-8.0 \* ULN that did not resolve to Grade 2 within 7 days and Grade 1 within 14 days; Grade 3 elevation of total bilirubin \>5 \* ULN; Any Grade 3 elevation of total bilirubin \>3.0-5.0 \* ULN that did not resolve to Grade 2 within 7 days and Grade 1 within 14 days; Any event meeting criteria for Hy's law. |
| Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | Up to approximately 3 years | ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | Up to approximately 3 years | DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method. |
| Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | Schedule A: Cycle 1 Day 1 (C1D1), C3D1; Schedule B: C1D1, C1D15 | — |
| Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation | Up to approximately 3 years | An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AEs with onset date between the first dose of IMGC936 and date of the last dose of IMGC936 + 30 days (inclusive) or date of the first anti-cancer therapy, whichever was earlier. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. |
| Dose Expansion Phase: Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 | Up to approximately 3 years | PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. |
| Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | Up to approximately 3 years | — |
| Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | Up to approximately 3 years | ORR was defined as percentage of participants with a confirmed BOR of CR or PR. CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the SoD of target lesions, taking as reference the baseline SoD. |
Countries
Italy, Spain, United States
Participant flow
Pre-assignment details
The study included a Dose Escalation and a Dose Expansion Phase.
Participants by arm
| Arm | Count |
|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg Participants received IMGC936 0.5 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 3 |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg Participants received IMGC936 1.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 3 |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg Participants received IMGC936 2.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 3 |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg Participants received IMGC936 4.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 3 |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg Participants received IMGC936 5.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 3 |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg Participants received IMGC936 6.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 10 |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg Participants received IMGC936 7.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 9 |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg Participants received IMGC936 2.0 mg/kg on Days 1, 8, and 15 of a 28-day cycle for the first 2 cycles. On all subsequent cycles (Cycle 3 and beyond), participants received IMGC936 3.0 mg/kg on Days 1 and 8 of a 28-day cycle. | 3 |
| Dose Expansion - NSCLC: IMGC936 6.0 mg/kg Participants received IMGC936 6.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 13 |
| Dose Expansion - TNBC: IMGC936 6.0 mg/kg Participants received IMGC936 6.0 mg/kg via IV infusion on Day 1 of Cycle 1 and every subsequent 21-day cycle thereafter. | 6 |
| Total | 56 |
Baseline characteristics
| Characteristic | Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Total | Dose Expansion - TNBC: IMGC936 6.0 mg/kg | Dose Expansion - NSCLC: IMGC936 6.0 mg/kg | Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation - Schedule A: IMGC936 1.0 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 54.7 years STANDARD_DEVIATION 5.51 | 61.1 years STANDARD_DEVIATION 8.57 | 55.8 years STANDARD_DEVIATION 10.96 | 64.8 years STANDARD_DEVIATION 8.8 | 61.0 years STANDARD_DEVIATION 5.57 | 63.4 years STANDARD_DEVIATION 8.46 | 60.4 years STANDARD_DEVIATION 7.63 | 61.3 years STANDARD_DEVIATION 9.81 | 67.7 years STANDARD_DEVIATION 5.69 | 59.3 years STANDARD_DEVIATION 4.93 | 53.3 years STANDARD_DEVIATION 8.39 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 3 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 49 Participants | 5 Participants | 11 Participants | 3 Participants | 9 Participants | 9 Participants | 3 Participants | 2 Participants | 2 Participants | 2 Participants |
| Sex: Female, Male Female | 2 Participants | 32 Participants | 6 Participants | 6 Participants | 2 Participants | 3 Participants | 3 Participants | 3 Participants | 2 Participants | 3 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 24 Participants | 0 Participants | 7 Participants | 1 Participants | 6 Participants | 7 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 1 / 3 | 1 / 3 | 0 / 3 | 1 / 3 | 1 / 10 | 2 / 9 | 1 / 3 | 3 / 13 | 0 / 6 |
| other Total, other adverse events | 3 / 3 | 3 / 3 | 3 / 3 | 3 / 3 | 3 / 3 | 10 / 10 | 9 / 9 | 3 / 3 | 13 / 13 | 6 / 6 |
| serious Total, serious adverse events | 1 / 3 | 0 / 3 | 1 / 3 | 0 / 3 | 1 / 3 | 1 / 10 | 4 / 9 | 2 / 3 | 4 / 13 | 2 / 6 |
Outcome results
Primary
Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0)
DLTs were defined based on TEAEs or abnormal laboratory values that met DLT criteria. Hematologic DLT: Grade 4 neutropenia lasting \>7 days; ≥Grade 3 febrile neutropenia Grade 4 thrombocytopenia; Grade 3 thrombocytopenia associated with bleeding; ≥Grade 3 hemolysis. Non-hematologic DLT: Any ≥Grade 3 non-hematologic event, including Grade 3 ocular symptoms and signs; Grade 2 AEs that were prolonged inordinately; • Hepatic laboratory abnormalities meeting Hy's law criteria; Eye pain or reduction in visual acuity that did not respond to topical ophthalmic therapy. Hepatic DLT: Any elevation of ≥1 transaminases \>8 \* upper limit of normal (ULN); Any Grade 3 elevation of ≥1 transaminases \>5.0-8.0 \* ULN that did not resolve to Grade 2 within 7 days and Grade 1 within 14 days; Grade 3 elevation of total bilirubin \>5 \* ULN; Any Grade 3 elevation of total bilirubin \>3.0-5.0 \* ULN that did not resolve to Grade 2 within 7 days and Grade 1 within 14 days; Any event meeting criteria for Hy's law.
Time frame: Cycle 1 (21 days for Schedule A and 28 days for Schedule B)
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) Based on National Cancer Institute (NCI) Common Terminology Criteria for AEs Version 5.0 (CTCAE v5.0) | 0 Participants |
Primary
Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious AEs (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AEs with onset date between the first dose of IMGC936 and date of the last dose of IMGC936 + 30 days (inclusive) or date of the first anti-cancer therapy, whichever was earlier. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Up to approximately 3 years
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 3 Participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 3 Participants |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 3 Participants |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 3 Participants |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 3 Participants |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 10 Participants |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 9 Participants |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 4 Participants |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | SAEs | 2 Participants |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Any TEAEs | 3 Participants |
Primary
Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ORR was defined as percentage of participants with a confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR: At least 30% decrease in the sum of the longest diameters (SoD) of target lesions, taking as reference the baseline SoD.
Time frame: Up to approximately 3 years
Population: Response evaluable population included all participants who received at least 1 dose of study drug, had baseline measurable or non-measurable disease, and had at least 1 post-baseline radiographic tumor assessment or discontinued study drug due to clinical progression or death if no post-baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 0 percentage of participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Expansion Phase: Objective Response Rate (ORR) - Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | 0 percentage of participants |
Secondary
Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1
DOR was defined as the time from the date of the first response (CR or PR), until the date of progressive disease (PD) or death from any cause, whichever occurred first. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. DOR was estimated using the Kaplan-Meier method.
Time frame: Up to approximately 3 years
Population: Response evaluable population included all participants who received at least 1 dose of study drug, had baseline measurable or non-measurable disease, and had at least 1 post-baseline radiographic tumor assessment or discontinued study drug due to clinical progression or death if no post-baseline tumor assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Expansion - NSCLC: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
| Dose Expansion - TNBC: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Duration of Response (DOR) as Assessed by the Investigator Using RECIST v1.1 | NA months |
Secondary
Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax)
Time frame: Schedule A: Cycle 1 Day 1 (C1D1), C3D1; Schedule B: C1D1, C1D15
Population: The Pharmacokinetics Analysis Set (PAS) included all participants who received at least one dose of IMGC936 and from whom results of plasma or serum concentrations were obtained for at least one sampling point.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 14.17 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 22 |
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C3D1 | NA micrograms/milliliter (μg/mL) | — |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 22.21 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 5.6 |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C3D1 | NA micrograms/milliliter (μg/mL) | — |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 56.69 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 14.2 |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 107.2 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 9.6 |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 114.8 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 30.7 |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C3D1 | NA micrograms/milliliter (μg/mL) | — |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 149.5 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 21.6 |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C3D1 | 168.4 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 16.4 |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C3D1 | NA micrograms/milliliter (μg/mL) | — |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 162.4 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 23.7 |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D15 | NA micrograms/milliliter (μg/mL) | — |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Maximum Study Drug Concentration (Cmax) | C1D1 | 51.74 micrograms/milliliter (μg/mL) | Geometric Coefficient of Variation 9.8 |
Secondary
Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA)
Time frame: Up to approximately 3 years
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 3 Participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 0 Participants |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 2 Participants |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 0 Participants |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 1 Participants |
| Dose Expansion - NSCLC: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 3 Participants |
| Dose Expansion - TNBC: IMGC936 6.0 mg/kg | Dose Escalation and Dose Expansion Phase: Number of Participants With Antidrug Antibodies (ADA) | 1 Participants |
Secondary
Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1
ORR was defined as percentage of participants with a confirmed BOR of CR or PR. CR: Disappearance of all target or non-target lesions. All pathological or non-pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least 30% decrease in the SoD of target lesions, taking as reference the baseline SoD.
Time frame: Up to approximately 3 years
Population: Response evaluable population included all participants who received at least 1 dose of study drug, had baseline measurable or non-measurable disease, and had at least 1 post-baseline radiographic tumor assessment or discontinued study drug due to clinical progression or death if no post-baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
| Dose Escalation - Schedule A: IMGC936 2.0 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
| Dose Escalation - Schedule A: IMGC936 4.0 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
| Dose Escalation - Schedule A: IMGC936 5.0 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
| Dose Escalation - Schedule A: IMGC936 6.0 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
| Dose Escalation - Schedule A: IMGC936 7.0 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
| Dose Escalation - Schedule B: IMGC936 2.0 mg/kg | Dose Escalation Phase: ORR - Percentage of Participants With Objective Response as Assessed by the Investigator Using RECIST v1.1 | 0 percentage of participants |
Secondary
Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as any AEs with onset date between the first dose of IMGC936 and date of the last dose of IMGC936 + 30 days (inclusive) or date of the first anti-cancer therapy, whichever was earlier. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Up to approximately 3 years
Population: Safety population included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation | Any TEAEs | 13 Participants |
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation | SAEs | 4 Participants |
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation | IMGC936 related TEAEs That Led to Discontinuation | 1 Participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation | SAEs | 2 Participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation | Any TEAEs | 6 Participants |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Expansion Phase: Number of Participants With TEAEs, SAEs, and IMGC936 Related TEAEs That Led to Discontinuation | IMGC936 related TEAEs That Led to Discontinuation | 1 Participants |
Secondary
Dose Expansion Phase: Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1
PFS was defined as the time from initiation of study drug until the date of PD or death whichever occurred first, estimated using the Kaplan-Meier method. PD: At least a 20% increase in the SoD of target lesion, taken as reference the smallest (nadir) SoD since and including baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of non-target lesions and appearance of new lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: Up to approximately 3 years
Population: Response evaluable population included all participants who received at least 1 dose of study drug, had baseline measurable or non-measurable disease, and had at least 1 post-baseline radiographic tumor assessment or discontinued study drug due to clinical progression or death if no post-baseline tumor assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Escalation - Schedule A: IMGC936 0.5 mg/kg | Dose Expansion Phase: Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 | 2.7 months |
| Dose Escalation - Schedule A: IMGC936 1.0 mg/kg | Dose Expansion Phase: Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 | 1.2 months |